全文获取类型
收费全文 | 8378篇 |
免费 | 564篇 |
国内免费 | 52篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 223篇 |
妇产科学 | 249篇 |
基础医学 | 1379篇 |
口腔科学 | 182篇 |
临床医学 | 901篇 |
内科学 | 1667篇 |
皮肤病学 | 181篇 |
神经病学 | 840篇 |
特种医学 | 291篇 |
外国民族医学 | 7篇 |
外科学 | 736篇 |
综合类 | 42篇 |
一般理论 | 2篇 |
预防医学 | 704篇 |
眼科学 | 86篇 |
药学 | 658篇 |
中国医学 | 19篇 |
肿瘤学 | 784篇 |
出版年
2024年 | 11篇 |
2023年 | 64篇 |
2022年 | 113篇 |
2021年 | 216篇 |
2020年 | 153篇 |
2019年 | 203篇 |
2018年 | 210篇 |
2017年 | 171篇 |
2016年 | 237篇 |
2015年 | 243篇 |
2014年 | 349篇 |
2013年 | 415篇 |
2012年 | 674篇 |
2011年 | 799篇 |
2010年 | 420篇 |
2009年 | 378篇 |
2008年 | 605篇 |
2007年 | 650篇 |
2006年 | 607篇 |
2005年 | 578篇 |
2004年 | 493篇 |
2003年 | 401篇 |
2002年 | 389篇 |
2001年 | 52篇 |
2000年 | 43篇 |
1999年 | 64篇 |
1998年 | 77篇 |
1997年 | 79篇 |
1996年 | 62篇 |
1995年 | 43篇 |
1994年 | 43篇 |
1993年 | 31篇 |
1992年 | 29篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 6篇 |
1988年 | 5篇 |
1987年 | 4篇 |
1986年 | 8篇 |
1985年 | 7篇 |
1984年 | 6篇 |
1983年 | 8篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1977年 | 2篇 |
1973年 | 2篇 |
1970年 | 4篇 |
1968年 | 2篇 |
排序方式: 共有8994条查询结果,搜索用时 15 毫秒
991.
Schubert J Hillmen P Röth A Young NS Elebute MO Szer J Gianfaldoni G Socié G Browne P Geller R Rother RP Muus P;TRIUMPH Study Investigators 《British journal of haematology》2008,142(2):263-272
In paroxysmal nocturnal haemoglobinuria (PNH), chronic destruction of PNH red blood cells (RBCs) by complement leads to anaemia and other serious morbidities. Eculizumab inhibits terminal complement-mediated PNH RBC destruction by targeting C5. In the phase III, double-blind, placebo-controlled, TRIUMPH study, eculizumab reduced haemolysis, stabilized haemoglobin levels, reduced transfusion requirements and improved fatigue in patients with PNH. Herein, we explored the effects of eculizumab on measures of anaemia in patients from the TRIUMPH study and the open-label SHEPHERD study, a more heterogeneous population. Eculizumab reduced haemolysis regardless of pretreatment transfusion requirements and regardless of whether or not patients became transfusion-dependent during treatment ( P < 0·001). Reduction in haemolysis was associated with increased PNH RBC counts ( P < 0·001) while reticulocyte counts remained elevated. Eculizumab-treated patients demonstrated significantly higher levels of haemoglobin as compared with placebo in TRIUMPH and relative to baseline levels in SHEPHERD ( P < 0·001 for each study). Eculizumab lowered transfusion requirement across multiple pretreatment transfusion strata and eliminated transfusion support in a majority of both TRIUMPH and SHEPHERD patients ( P < 0·001). Patients who required some transfusion support during treatment with eculizumab showed a reduction in haemolysis and transfusion requirements and an improvement in fatigue. Eculizumab reduces haemolysis and improves anaemia and fatigue, regardless of transfusion requirements. 相似文献
992.
Petra Steindl‐Munda Peter Ferenci Harald Brunner Karin Nachbaur Christian Datz Michael Gschwantler Harald Hofer Rudolf Stauber Franz Hackl Wolfgang Jessner Martha Rosenbeiger Alfred Gangl Wolfgang Vogel 《Liver international》2003,23(4):269-275
Background/aims: Initial high‐dose interferon‐α induction therapy in combination with ribavirin improves sustained response rates in treatment‐naïve patients. This prospective, randomized, controlled study tested whether non‐responders or relapsers to interferon monotherapy also benefit from induction therapy. Methods: Patients with chronic hepatitis C who had not responded to (n=75) or relapsed (n=80) after previous interferon therapy were randomized to receive three different interferon doses during the first 14 weeks of therapy (A: 10 MU IntronA®/day for 2 weeks, followed by 10 MU/2 days for 12 weeks; B:5 MU/d for 14 weeks; C: 5 MU/2 days for 14 weeks) followed in all by 5 MU/2 days for 24 weeks. All patients received 1–1.2 g ribavirin/day throughout the whole study. Results: The rates of viral clearance at any time on treatment were similar in all groups. Sustained response rates were also not different among the groups in interferon nonresponders (A 32%, B 29%, C 31%) and relapsers (A 64%, B 68%, C 71%), respectively, as well as in patients with different genotypes. As expected, sustained response rates were higher in patients with genotype non‐1 than in those with genotype 1. Conclusion: High‐dose induction therapy does not improve the outcome of interferon/ribavirin therapy in interferon nonresponders or relapsers. 相似文献
993.
Rabausch K Bretschneider E Sarbia M Meyer-Kirchrath J Censarek P Pape R Fischer JW Schrör K Weber AA 《Circulation research》2005,96(1):e1-e6
There is concern that cyclooxygenase (COX)-2 inhibitors may promote atherothrombosis by inhibiting vascular formation of prostacyclin (PGI2) and an increased thrombotic risk of COX-2 inhibitors has been reported. It is widely accepted that the prothrombotic effects of COX-2 inhibitors can be explained by the removal of platelet-inhibitory PGI2. Using microarray chip technology, we have previously demonstrated that thrombomodulin (TM) mRNA is upregulated in cultured human coronary artery smooth muscle cells by the stable prostacyclin mimetic iloprost. This study is the first to demonstrate a stimulation of the expression of functionally active thrombomodulin in human smooth muscle cells by prostaglandins, endogenously formed via the COX-2 pathway. Because TM is an important inhibitor of blood coagulation, these findings provide a novel platelet-independent mechanism to explain the prothrombotic effects of COX-2 inhibitors. The full text of this article is available online at http://circres.ahajournals.org. 相似文献
994.
Immunological findings in whole and parotid saliva of patients with Crohn's disease and healthy controls 总被引:2,自引:0,他引:2
Graciela Crama-Bohbouth MD Petra Lems-Van Kan Irene T. Weterman MD PhD I. Biemond BSc Dr. A. S. Peña MD PhD 《Digestive diseases and sciences》1984,29(12):1089-1092
Since oral lesions appear to occur more commonly in patients with Crohn's disease (CD) than in normal controls or patients with ulcerative colitis, it has been suggested that a deficit of locally produced IgA allows the invasion of the oral mucous membrane by antigens and contributes to the production of oral lesions. in connection with this hypothesis, the concentrations of IgA, IgM, and IgG in whole and parotid saliva were investigated by the ELISA technique in 20 patients with CD and 20 healthy subjects matched for dental status. IgA predominated in whole and parotid saliva in both patients and controls, and in both groups whole saliva had higher levels of IgA, IgM, and IgG than parotid saliva did. Compared with the controls, IgA, IgM, and IgG levels were significantly elevated in the whole saliva of CD patients. However, no correlation was found between immunoglobulin levels and age, sex, therapy, duration, localization, or activity of the disease. 相似文献
995.
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study 总被引:13,自引:1,他引:13
Girolami B Prandoni P Stefani PM Tanduo C Sabbion P Eichler P Ramon R Baggio G Fabris F Girolami A 《Blood》2003,101(8):2955-2959
Although heparin-induced thrombocytopenia (HIT) is a known complication of intravenous unfractionated heparin (UFH), its incidence in medical patients treated with subcutaneous UFH is less well defined. To determine the incidence of HIT in this category of patients, the platelet count was performed at baseline and then every 3 +/- 1 days in 598 consecutive patients admitted to 2 medical wards and treated with subcutaneous UFH for prophylactic (n = 360) or therapeutic (n = 238) indications. The diagnosis of HIT was accepted in the case of a platelet drop of 50% or more and either the demonstration of heparin-dependent antibodies or (when this search could not be performed) the combination of the following features: (1) the absence of any other obvious clinical explanation for thrombocytopenia, (2) the occurrence of thrombocytopenia at least 5 days after heparin start, and (3) either the normalization of the platelet count within 10 days after heparin discontinuation or the earlier patient's death due to an unexpected thromboembolic complication. HIT developed in 5 patients (0.8%; 95% CI, 0.1%-1.6%); all of them belonged to the subgroup of patients who received heparin for prophylactic indications. The prevalence of thromboembolic complications in patients with HIT (60%) was remarkably higher than that observed in the remaining 593 patients (3.5%), leading to an odds ratio of 40.8 (95% CI, 5.2-162.8). Although the frequency of HIT in hospitalized medical patients treated with subcutaneous heparin is lower than that observed in other clinical settings, this complication is associated with a similarly high rate of thromboembolic events. 相似文献
996.
Szotowski B Goldin-Lang P Antoniak S Bogdanov VY Pathirana D Pauschinger M Dörner A Kuehl U Coupland S Nemerson Y Hummel M Poller W Hetzer R Schultheiss HP Rauch U 《Journal of the American College of Cardiology》2005,45(7):1081-1089
OBJECTIVES: We investigated the myocardial localization and expression of tissue factor (TF) and alternatively spliced human tissue factor (asHTF) in patients with dilated cardiomyopathy (DCM). BACKGROUND: Tissue factor is expressed in cardiac muscle and may play a role in maintaining myocardial structure. METHODS: Myocardial biopsies were obtained from patients with a normal or mildly impaired ejection fraction (EF) (> or =50%) and moderate to severely reduced EF (<50%). Explanted DCM hearts were also examined. Myocardial TF expression level was assessed by real-time polymerase chain reaction, TF protein by enzyme-linked immunosorbent assay, and localization by immunohistochemistry. RESULTS: We report the identification of asHTF in the human myocardium: it was located in cardiomyocytes and endothelial cells. Quantification of myocardial TF messenger ribonucleic acid in DCM revealed a decrease in the TF/glyceraldehyde-3-phosphate dehydrogenase (GAPDH) ratio (1.76 x 10(-1) +/- 6.08 x 10(-2) for EF > or =50% [n = 19] vs. 1.06 x 10(-1) +/- 5.26 x 10(-2) for EF <50% [n = 27]; p < 0.001) and asHTF/GAPDH ratio (13.91 x 10(-5) +/- 11.20 x 10(-5) for EF > or =50% vs. 7.17 x 10(-5) +/- 3.82 x 10(-5) for EF <50%; p = 0.014). Tissue factor isoform expression level was also decreased in explanted DCM hearts (p < 0.01; n = 12). Total TF protein was reduced by 26% in DCM (p < 0.05). The TF/GAPDH ratio correlated positively with the EF (r = 0.504, p < 0.0001). Immunohistochemistry showed TF localized to the sarcolemma and Z-bands of the cardiomyocytes in patients with normal EF, whereas TF was found in the cardiomyocytic cytosol around the nucleus in DCM. CONCLUSIONS: Tissue factor was down-regulated in the myocardium of DCM patients. The reduction in TF expression and change in localization may influence cell-to-cell contact stability and contractility, thereby contributing to cardiac dysfunction in DCM. 相似文献
997.
Giltay EJ Verhoef P Gooren LJ Geleijnse JM Schouten EG Stehouwer CD 《Atherosclerosis》2003,168(1):139-146
Plasma total homocysteine (tHcy) levels are on average lower in women versus men, indicating an estrogenic effect. Oral estrogens (absorbed via the liver) may be hypothesized to have stronger effects on hepatic homocysteine metabolism than transdermal estrogens. We randomly assigned 30 male-to-female transsexuals (20-44 years old) to 4 months' administration of oral ethinyl estradiol (n=15) or transdermal 17beta-estradiol (n=15), both with the antiandrogen cyproterone acetate (CA). Ten other male controls were treated with CA only. At baseline and after 2 and 4 months, plasma tHcy was analyzed in conjunction with plasma folate. Oral ethinyl estradiol and transdermal 17beta-estradiol similarly reduced plasma tHcy (geometric mean 10.6 micromol/l [95% CI 8.2-13.9] to 7.5 [6.5; 8.8], and 11.3 [8.1; 16.4] to 8.4 [6.5; 11.1]; P<0.001 for both), whereas CA had no effects. No effects were found on folate levels. Thus, oral and transdermal estrogens decrease plasma tHcy to a similar degree (by geometric mean -26%), which suggests that a hepatic mechanism is unlikely to play an important role in the decline of tHcy levels. 相似文献
998.
Jilma-Stohlawetz P Homoncik M Jilma B Knechtelsdorfer M Unger P Mannhalter C Santoso S Panzer S 《British journal of haematology》2003,120(4):652-655
Platelet polymorphisms (Kozak, VNTR and HPA-2) within glycoprotein (GP)Ib alpha may be associated with an increased risk of arterial thrombosis. However, the functional role of these polymorphisms has not been clarified. Their influence on platelet plug formation under high shear rates was, therefore, examined in 233 healthy individuals. Collagen-adrenaline-induced closure time was shorter in carriers of the C/D versus C/C VNTR allele and in homozygotes with the (-5)T/T versus (-5)C/T Kozak genotype as determined by novel polymerase chain reaction methods. The HPA-2 genotype had no effects, and the density of GPIb alpha molecules was not influenced by GPIb alpha genotypes. 相似文献
999.
1000.
Mutations in bone morphogenetic protein receptor 1B cause brachydactyly type A2 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Lehmann K Seemann P Stricker S Sammar M Meyer B Süring K Majewski F Tinschert S Grzeschik KH Müller D Knaus P Nürnberg P Mundlos S 《Proceedings of the National Academy of Sciences of the United States of America》2003,100(21):12277-12282
Brachydactyly (BD) type A2 is an autosomal dominant hand malformation characterized by shortening and lateral deviation of the index fingers and, to a variable degree, shortening and deviation of the first and second toes. We performed linkage analysis in two unrelated German families and mapped a locus for BD type A2 to 4q21-q25. This interval includes the gene bone morphogenetic protein receptor 1B (BMPR1B), a type I transmembrane serinethreonine kinase. In one family, we identified a T599 --> A mutation changing an isoleucine into a lysine residue (I200K) within the glycine/serine (GS) domain of BMPR1B, a region involved in phosphorylation of the receptor. In the other family we identified a C1456 --> T mutation leading to an arginine-to-tryptophan amino acid change (R486W) in a highly conserved region C-terminal of the BMPR1B kinase domain. An in vitro kinase assay showed that the I200K mutation is kinase-deficient, whereas the R486W mutation has normal kinase activity, indicating a different pathogenic mechanism. Functional analyses with a micromass culture system revealed a strong inhibition of chondrogenesis by both mutant receptors. Overexpression of mutant chBmpR1b in vivo in chick embryos by using a retroviral system resulted either in a BD phenotype with shortening and/or missing phalanges similar to the human phenotype or in severe hypoplasia of the entire limb. These findings imply that both mutations identified in human BMPR1B affect cartilage formation in a dominant-negative manner. 相似文献